Chemotherapy and target therapy in the management of adult high-grade gliomas

Current Cancer Drug Targets

Volumn 12, Issue 8, 2012, Pages 1016-1031

  Spinelli, Gian Paolo ^a   Miele, Evelina ^a   Lo Russo, Giuseppe ^a   Miscusi, Massimo ^a   Codacci Pisanelli, Giovanni ^a   Petrozza, Vincenzo ^a   Papa, Anselmo ^a   Frati, Luigi ^a   Della Rocca, Carlo ^a   Gulino, Alberto ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti angiogenic agents; Anti EGFR agents; Chemotherapy; High grade gliomas; Target therapy; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARMUSTINE; CETUXIMAB; CILENGITIDE; CYCLOPHOSPHAMIDE; DACARBAZINE; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FOTEMUSTINE; GEFITINIB; IRINOTECAN; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITROSOUREA DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PROCARBAZINE; SEMUSTINE; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

ANOREXIA; BLOOD TOXICITY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM TUMOR; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATALITY; FATIGUE; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; LIFE EXPECTANCY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOMA; HUMANS; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROMOTER REGIONS, GENETIC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84867794646     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912803251207     Document Type: Review

References (173)

1. Louis, D. N.; Ohgaki, H.; Wiestler, O. D.; Cavenee, W. K.; Burger, P. C.; Jouvet, A.; Scheithauer, B. W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114(2), 97-109.
2. Kleihues, P.; Louis, D. N.; Scheithauer, B. W.; Rorke, L. B.; Reifenberger, G.; Burger, P. C.; Cavenee, W. K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 2002, 61(3), 215-229.
3. Brat, D. J.; Parisi, J. E.; Kleinschmidt-DeMasters, B. K.; Yachnis, A. T.; Montine, T. J.; Boyer, P. J.; Powell, S. Z.; Prayson, R. A.; McLendon, R. E. Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch. Pathol. Lab. Med. 2008, 132(6), 993-1007.
4. Purow, B.; Schiff, D. Advances in the genetics of glioblastoma: are we reaching a critical mass? Nat. Rev. Neurol. 2009, 5(8), 419-426.
5. Ohgaki, H.; Kleihues, P. Genetic pathways to primary and secondary glioblastloma. Am. J. Pathol. 2007, 170(5), 1445-1453.
6. Ohgaki, H.; Dessen, P.; Jourde, B.; Horstmann, S.; Nishikawa, T.; Di Patre, P. L.; Burkhard, C.; Schüler, D.; Probst-Hensch, N. M.; Maiorka, P.C.; Baeza, N.; Pisani, P.; Yonekawa, Y.; Yasargil, M. G.; Lütolf, U. M.; Kleihues, P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64(19), 6892-6899.
7. Stupp, R.; Mason, W. P.; Van Den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352(10), 987-996.
8. Brandes, A. A.; Tosoni, A.; Franceschi, E.; Reni, M.; Gatta, G.; Vecht, C. Glioblastoma in adults. Crit. Rev. Oncol. Hematol. 2008, 67(2), 139-152.
9. Wen, P. Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med 2008, 359(5), 492-507.
10. Yung, W. K.; Albright, R. E.; Olson, J.; Fredericks, R.; Fink, K.; Prados, M. D.; Brada, M.; Spence, A.; Hohl, R. J.; Shapiro, W.; Glantz, M.; Greenberg, H.; Selker, R. G.; Vick, N. A.; Rampling, R.; Friedman, H.; Phillips, P.; Bruner, J.; Yue, N.; Osoba, D.; Zaknoen, S.; Levin, V. A. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 2000, 83(5), 588-593.
11. Wong, E. T.; Hess, K. R.; Gleason, M. J.; Jaeckle, K. A.; Kyritsis, A. P.; Prados, M. D.; Levin, V. A.; Yung, W. K. Outcomes and prognostic factors in recurrent glioma patients enrolled phase II clinical Trials. J. Clin. Oncol. 1999, 17(8), 2572-2578.
12. Furnari, F. B.; Fenton, T.; Bachoo, R. M.; Mukasa, A.; Stommel, J. M.; Stegh, A.; Hahn, W. C.; Ligon, K. L.; Louis, D. N.; Brennan, C.; Chin, L.; De Pinho, R. A.; Cavenee, W. K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21(21), 2683-2710.
13. Mischel, P. S.; Shai, R.; Shi, T.; Horvath, S.; Lu, K. V.; Choe, G.; Seligson, D.; Kremen, T. J.; Palotie, A.; Liau, L. M.; Cloughesy, T. F.; Nelson, S. F. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003, 22(15), 2361-2373.
14. Choe, G.; Horvath, S.; Cloughesy, T. F.; Crosby, K.; Seligson, D.; Palotie, A.; Inge, L.; Smith, B. L.; Sawyers, C. L.; Mischel, P. S. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003, 63(11), 2742-2746.
15. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008, 321(5897), 1807-1812.
16. Yan, H.; Parsons, D. W.; Jin, G.; McLendon, R.; Rasheed, B. A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G. J.; Friedman, H.; Friedman, A.; Reardon, D.; Herndon, J.; Kinzler, K. W.; Velculescu, V. E.; Vogelstein, B.; Bigner, D. D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360(8), 765-773.
17. Jensen, R. L. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J. Neurooncol. 2009, 92(3), 317-335.
18. Walker, M. D.; Alexander, E.; Hunt, W. E.; MacCarty, C. S.; Mahaley, M. S.; Mealey, J.; Norrell, H. A.; Owens, G.; Ransohoff, J.; Wilson, C. B.; Gehan, E. A.; Strike, T. A. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J. Neurosurg. 1978, 49(3), 333-343.
19. Walker, M. D.; Green, S. B.; Byar, D. P.; Alexander, E.; Batzdorf, U.; Brooks, W. H.; Hunt, W. E.; MacCarty, C. S.; Mahaley, M. S.; Mealey, J.; Owens, G.; Ransohoff, J.; Robertson, J. T.; Shapiro, W. R.; Smith, K. R.; Wilson, C. B.; Strike, T. A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 1980, 303(23), 1323-1329.
20. Chang, C. H.; Horton, J.; Schoenfeld, D.; Salazer, O.; Perez-Tamayo, R.; Kramer, S.; Weinstein, A.; Nelson, J. S.; Tsukada, Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983, 52(6), 997-1007.
21. Spiegel, B. M.; Esrailian, E.; Laine, L.; Chamberlain, M. C. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 2007, 21(9), 775-787.
22. Stewart, L. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002, 359(9311), 1011-1018.
23. Wedge, S. R.; Porteous, J. K.; Glaser, M. G.; Marcus, K.; Newlands, E. S. In vitro evaluation of temozolomide combined with X-irradiation. Anti-Cancer Drugs 1997, 8(1), 92-97.
24. van Rijn, J.; Heimans, J. J.; van den Berg, J.; van der Valk, P.; Slotman, B. J. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47(3), 779-784.
25. Chakravarti, A.; Erkkinen, M. G.; Nestler, U.; Stupp, R.; Mehta, M.; Aldape, K.; Gilbert, M. R.; Black, P. M.; Loeffler, J. S. Temozolomide mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin. Cancer Res. 2006, 12(15), 4738-4746.
26. Brandes, A. A.; Vastola, F.; Basso, U.; Berti, F.; Pinna, G.; Rotilio, A.; Gardiman, M.; Scienza, R.; Monfardini, S.; Ermani, M. A prospective study on glioblastoma in the elderly. Cancer 2003, 97(3), 657-662.
27. Stupp, R.; Hegi, M. E.; Mason, W. P.; van den Bent, M. J.; Taphoorn, M. J.; Janzer, R. C.; Ludwin, S. K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A. A.; Gijtenbeek, J.; Marosi, C.; Vecht, C. J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J. G.; Mirimanoff, R. O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10(5), 459-466.
28. MacDonald, D. R.; Kiebert, G.; Prados, M.; Yung, A.; Olson, J. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning performance status and health related quality of life. Cancer Invest. 2005, 23(2), 138-144.
29. Brandes, A. A.; Tosoni, A.; Cavallo, G.; Bertorelle, R.; Gioia, V.; Franceschi, E.; Biscuola, M.; Blatt, V.; Crinò, L.; Ermani, M. Temozolomide three weeks on and 1 week off as first line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neurooncologia (GICNO). Br. J. Cancer 2006, 95(9), 1155-1160.
30. Perry, J. R.; Rizek, P.; Cashman, R.; Morrison, M.; Morrison, T. Temozolomide rechallenge in recurrent malignant glioma by using a continous temozolomide schedule: the "rescue" approach. Cancer 2008, 113(8), 2152-2157.
31. Wick, A.; Felsberg, J.; Steinbach, J. P.; Herrlinger, U.; Platten, M.; Blaschke, B.; Meyermann, R.; Reifenberger, G.; Weller, M.; Wick, W. Efficacy and tolerability of temozolomide in an alternanting weekly regimen in patients with recurrent glioma. J. Clin. Oncol. 2007, 25(22), 3357-3361.
32. Gerson, S. L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004, 4(4), 296-307.
33. Chakravarti, A.; Tyndall, E.; Palanichamy, K.; Mehta, M.; Aldape, K.; Loeffler, J. Impact of molecular profiling on clinical trial design for glioblastoma. Curr. Oncol. Rep. 2007, 9(1), 71-79.
34. Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; Bromberg, J. E.; Hau, P.; Mirimanoff, R. O.; Cairncross, J. G.; Janzer, R. C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352(10), 997-1003.
35. Sarkaria, J. N.; Kitange, G. J.; Plummer, D. J.; Calvert, H.; Weller, M.; Wick, W. Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clin. Cancer Res. 2008, 14(10), 2900-2908.
36. Tolcher, A. W.; Gerson, S. L.; Denis, L.; Geyer, C.; Hammond, L. A.; Patnaik, A.; Goetz, A. D.; Schwartz, G.; Edwards, T.; Reyderman, L.; Statkevich, P.; Cutler, D. L.; Rowinsky, E. K. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer 2003, 88(7), 1004-1011.
37. Friedman, H. S. Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic? Clin. Cancer Res. 2000, 6(8), 2967-2968.
38. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 2005, 23(28), 7178-7187.
39. Quinn, J. A.; Jiang, S. X.; Reardon, D. A.; Desjardins, A.; Vredenburgh, J. J.; Rich, J. N.; Gururangan, S.; Friedman, A. H.; Bigner, D. D.; Sampson, J. H.; McLendon, R. E.; Herndon, J. E.; Walker, A.; Friedman, H. S. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009, 11(5), 556-561.
40. Quinn, J. A.; Jiang, S. X.; Reardon, D. A.; Desjardins, A.; Vredenburgh, J. J.; Rich, J. N.; Gururangan, S.; Friedman, A. H.; Bigner, D. D.; Sampson, J. H.; McLendon, R. E.; Herndon, J. E.; Walker, A.; Friedman, H. S. Phase II trial of Temozolomide Plus O6-Benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 2009, 27(8), 1262-1267.
41. Donawho, C. K.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S.; Grimm, D. R.; Guan, R.; Han, E. K.; Holley-Shanks, R. R.; Hristov, B.; Idler, K. B.; Jarvis, K.; Johnson, E. F.; Kleinberg, L. R.; Klinghofer, V.; Lasko, L. M.; Liu, X.; Marsh, K. C.; McGonigal, T. P.; Meulbroek, J. A.; Olson, A. M.; Palma, J. P.; Rodriguez, L. E.; Shi, Y.; Stavropoulos, J. A.; Tsurutani, A. C.; Zhu, G. D.; Rosenberg, S. H.; Giranda, V. L.; Frost, D. J. ABT-888, an orally active poly(ADP ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13(9), 2728-2737.
42. Miknyoczki, S.; Chang, H.; Grobelny, J.; Pritchard, S.; Worrell, C.; McGann, N.; Ator, M.; Husten, J.; Deibold, J.; Hudkins, R.; Zulli, A.; Parchment, R.; Ruggeri, B. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increasesthe sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol. Cancer Ther. 2007, 6(8), 2290-2302.
43. Dungey, F. A.; Löser, D. A.; Chalmers, A. J. Replicationdependent radiosensitization of human glioma cells by inhibition of Poly(ADP-Ribose) Polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72(4), 1188-1197.
44. Liu, L.; Gerson, S. L. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res. 2006, 12(2), 328-331.
45. Russo, A. L.; Kwon, H. C.; Burgan, W. E.; Carter, D.; Beam, K.; Weizheng, X.; Zhang, J.; Slusher, B. S.; Chakravarti, A.; Tofilon, P. J.; Camphausen, K. In vitro and In vivo radiosensibilization of glioblastoma cells by the Poly (ADP-Ribose) Polymerase inhibitor E7016. Clin. Cancer Res. 2009, 15(2), 607-612.
46. Leonetti, C.; Biroccio, A.; Graziani, G.; Tentori, L. Targeted therapy for brain tumours: role of PARP inhibitors. Curr. Cancer Drug Targets 2012, 12(3), 218-236.
47. Meulemans, A.; Giroux, B.; Hannoun, P.; Robine, D.; Henzel, D. Comparative diffusion study of two nitrosureas: carmustine and fotemustine in normal rat brain, Human and rat brain biopsies. Chemotherapy 1991, 37(2), 86-92.
48. Levin, V. A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 1980, 23(6), 682-684.
49. Fischel, J. L.; Formento, P.; Etienne, M. C.; Gioanni, J.; Frenay, M.; Deloffre, P.; Bizzari, J. P.; Milano, G. In vitro chemiosensivity testing of fotemustine (S 10036) a new antitumor nitrosurea. Cancer Chemother. Pharmacol. 1990, 25(5), 337-341.
50. Khayat, D.; Lokiec, F.; Bizzari, J. P.; Weil, M.; Meeus, L.; Sellami, M.; Rouesse, J.; Banzet, P.; Jacquillat, C. Phase I clinical study of the new amino-acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res. 1987, 47(24), 6782-6785.
51. Fabrini, M. G.; Silvano, G.; Lolli, I.; Perrone, F.; Marsella, A.; Scotti, V.; Cionini, L. A multiistutional phase II study on second line fotemustine chemotharapy in recurrent glioblastoma. J. Neurooncol. 2009, 92(1), 79-86.
52. Scoccianti, S.; Detti, B.; Sardaro, A.; Iannalfi, A.; Meattini, I.; Leonulli, B. G.; Borghesi, S.; Martinelli, F.; Bordi, L.; Ammannati, F.; Biti, G. Second line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 2008, 19(6), 613-620.
53. Brandes, A. A.; Tosoni, A.; Franceschi, E.; Blatt, V.; Santoro, A.; Faedi, M.; Amistà, P.; Gardiman, M.; Labianca, R.; Bianchini, C.; Ermani, M.; Reni, M. Fotemustine as second line treatment for recurrent of progressive glioblatoma after concomitant and / or adjuvat temozolomide: a phase II trail of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol. 2009, 64(4), 769-775.
54. Fabi, A.; Metro, G.; Russillo, M.; Vidiri, A.; Carapella, C. M.; Maschio, M.; Cognetti, F.; Jandolo, B.; Mirri, M. A.; Sperduti, I.; Telera, S.; Carosi, M.; Pace, A. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. BMC Cancer 2009, 9, 101.
55. Silvani, A.; Lamperti, E.; Gaviani, P.; Eoli, M.; Fiumani, A.; Salmaggi, A.; Falcone, C.; Filippini, G.; Botturi, A.; Boiardi, A. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J. Neurooncol. 2008, 87(2), 143-151.
56. Fazeny-Dorner, B.; Veitlb, M.; Wenzela, C.; Piribauer, M.; Rössler, K.; Dieckmann, K.; Ungersböc, K.; Marosi, C. Second line chemotherapy with dacarbazine and fotemustine in nitrosureapretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 2003, 14(6), 437-442.
57. Brandes, A. A.; Tosoni, A.; Amista, P.; Nicolardi, L.; Grosso, D.; Berti, F.; Ermani, M. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004, 63(7), 1281-1284.
58. Kappelle, A. C.; Postma, T. J.; Taphoom, M. J.; Groeneveld, G. J.; van den Bent, M. J.; van Groeningen, C. J.; Zonnenberg, B. A.; Sneeuw, K. C.; Heimans, J. J. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 2001, 56(1), 118-120.
59. Newton, H. B.; Junck, L.; Bromberg, J.; Page, M. A.; Greenberg, H. S. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 1990, 40(11), 1743-1746.
60. Rodriguez, L. A.; Prados, M.; Silver, P.; Levin, V. A. Revalutation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989, 64(12), 2420-2423.
61. Chamberlain, M. C.; Tsao-Wie, D. D. Salvage chemotherapy with ciclophosphamide for recurrent tomozolomide-refractory glioblastoma multiforme. Cancer 2004, 100(6), 1213-1220.
62. Brandes, A. A.; Tosoni, A.; Basso, U.; Reni, M.; Valduga, F.; Monfardini, S.; Amistà, P.; Nicolardi, L.; Sotti, G.; Ermani, M. Second line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neurooncologia (GICNO). J. Clin. Oncol. 2004, 22(23), 4779-4786.
63. Gertler, S. Z.; MacDonald, D.; Goodyear, M.; Forsyth, P.; Stewart, D. J.; Belanger, K.; Perry, J.; Fulton, D.; Steward, W.; Wainman, N.; Seymour, L. NCIC-CTG phase II study of gemcitabine in patients with malignant glioma. Ann. Oncol. 2000, 11(3), 315-318.
64. Chamberalin, M. C.; Kormanik, P. Salvage chemotherapy with taxol for recurrent anaplastic astrocitoma. J. Neurooncol. 1999, 43(1), 71-78.
65. Sanson, M.; Napolitano, M.; Yaya, R.; Keime-Guibert, F.; Broët, P.; Hoang-Xuan, K.; Delattre, J. Y. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J. Neurooncol. 2000, 50(3), 245-249.
66. Libermann, T. A.; Nusbaum, H. R.; Razon, N.; Kris, R.; Lax, I.; Soreq, H.; Whittle, N.; Waterfield, M. D.; Ullrich, A.; Schlessinger, J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313(5998), 144-147.
67. Ke, L. D.; Shi, Y. X.; Im, S. A.; Chen, X.; Yung, W. K. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity I human glioma cell lines. Clin. Cancer Res. 2000, 6(6), 2562-2572.
68. Chaudhry, L. H.; O'Donovan, D. G.; Brenchley, P. E.; Reid, H.; Roberts, I. S. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001, 39(4), 409-415.
69. Chi, A. S.; Sorensen, A. G.; Jain, R. K.; Batchelor, T. T. Angiogenesis as a therapeutic target in malignant Gliomas. Oncologist 2009, 14(6), 621-636.
70. Caraglia, M.; Addeo, R. Editorial: target therapy in brain tumours and metastases. Curr. Cancer Drug Targets 2012, 12(3), 185.
71. Schmidt, N. O.; Westphal, M.; Hagel, C.; Ergün, S.; Stavrou, D.; Rosen, E. M.; Lamszus, K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 1999, 84(1), 10-18.
72. Sugawa, N.; Ekstrand, A. J.; James, C. D.; Collins, V. P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 1999, 87(21), 8602-8606.
73. Frederick, L.; Wang, X. Y.; Eley, G.; James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60(5), 1383-1387.
74. Nishikawa, R.; Ji, X. D.; Harmon, R. C.; Lazar, C. S.; Gill, G. N.; Cavenee, W. K.; Huang, H. J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA 1994, 91(16), 7727-7731.
75. Nagane, M.; Coufal, F.; Lin, H.; Bögler, O.; Cavenee, W. K.; Huang, H. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996, 56(21), 5079-5086.
76. Huang, H. S.; Nagane, M.; Klingbeil, C. K.; Lin, H.; Nishikawa, R.; Ji, X. D.; Huang, C. M.; Gill, G. N.; Wiley, H. S.; Cavenee, W. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 1997, 272(5), 2927-2935.
77. Narita, Y.; Nagane, M.; Mishima, K.; Huang, H. J.; Furnari, F. B.; Cavenee, W. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002, 62(22), 6764-6769.
78. Jain, R. K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 2005, 307(5706), 58-62.
79. Presta, L. G.; Chen, H.; O'Connor, S. J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57(20), 4593-4599.
80. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362(6423), 841-844.
81. Ferrara, N.; Hillan, K. J.; Gerber, H.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3(5), 391-400.
82. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel carboplatin alone or with bevacizumab for non-small cell lung cancer. N. Engl. J. Med. 2006, 355(24), 2542-2550.
83. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E. A.; Shenkier, T.; Cella, D.; Davidson, N. E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357(26), 2666-2676.
84. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N. Engl. J. Med. 2004, 350(23), 2335-2342.
85. Soffietti, R.; Trevisan, E.; Bertero, L.; Bosa, C.; Ruda, R. Antiangiogenic approaches to malignant gliomas. Curr. Cancer Drug Targets 2012, 12(3), 279-288.
86. Lai, A.; Filka, E.; McGibbon, B.; Nghiemphu, P. L.; Graham, C.; Yong, W. H.; Mischel, P.; Liau, L. M.; Bergsneider, M.; Pope, W.; Selch, M.; Cloughesy, T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71(5), 1372-1380.
87. Lai, A.; Tran, A.; Nghiemphu, P. L.; Pope, W. B.; Solis, O. E.; Selch, M.; Filka, E.; Yong, W. H.; Mischel, P. S.; Liau, L. M.; Phuphanich, S.; Black, K.; Peak, S.; Green, R. M.M.; Spier, C. E.; Kolevska, T.; Polikoff, J.; Fehrenbacher, L.; Elashoff, R.; Cloughesy, T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 2011, 29(2), 142-148.
88. Vredenburgh, J. J.; Desjardins, A.; Kirkpatrick, J. P.; Reardon, D. A.; Peters, K. B,.; Herndon, J. E.; Marcello, J.; Bailey, L.; Threatt, S.; Sampson, J.; Friedman, A.; Friedman, H. S. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82(1), 58-66.
89. Narayana, A.; Golfinos, J. G.; Fischer, I.; Raza, S.; Kelly, P.; Parker, E.; Knopp, E. A.; Medabalmi, P.; Zagzag, D.; Eagan, P.; Gruber, M. L. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72(2), 383-389.
90. Narayana, A.; Gruber, D.; Kunnakkat, S.; Golfinos, J. G.; Parker, E.; Raza, S.; Zagzag, D.; Eagan, P.; Gruber, M. L. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg. 2012, 116(2), 341-345.
91. Vredenburgh, J. J.; Desjardins, A.; Reardon, D. A.; Peters, K. B.; Marcello, J.; Kirkpatrick, J. P.; Sampson, J. H.; Bailey, L.; Threatt, S.; Friedman, A. H.; Bigner, D. D.; Friedman, H. S. The addition of bevacizumab to standard radiationtherapy and temozolomide followedby bevacizumb, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res. 2011, 17(12), 4119-4124.
92. Chinot, O. L.; de La Motte Rouge T.; Moore, N.; Zeaiter, A.; Das, A.; Phillips, H.; Modrusan, Z.; Cloughesy, T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 2011, 28(4), 334-340.
93. Vredenburg, J. J.; Desjardinis, A.; Herdon, J. E.; Marcello, J.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D. D.; Friedman, A. H.; Friedman, H. S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25(30), 4722-4729.
94. Nghiemphu, P. L.; Liu, W.; Lee, Y.; Than, T.; Graham, C.; Lai, A.; Green, R. M.; Pope, W. B.; Liau, L. M.; Mischel, P. S.; Nelson, S. F.; Elashoff, R.; Cloughesy, T. F. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009, 72(14), 1217-1222.
95. Narayana, A.; Kelly, P.; Golfinos, J.; Parker, E.; Johnson, G.; Knopp, E.; Zagzag, D.; Fischer, I.; Raza, S.; Medabalmi, P.; Eagan, P.; Gruber, M. L. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009, 110(1), 173-180.
96. Poulsen, H. S.; Grunnet, K.; Sorensen, M.; Olsen, P.; Hasselbalch, B.; Nelausen, K.; Kosteljanetz, M.; Lassen, U. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009, 48(1), 52-58.
97. Zuniga, R. M.; Torcuator, R.; Jain, R.; Anderson, J.; Doyle, T.; Ellika, S.; Schultz, L.; Mikkelsen, T. Efficacy, safety and patterns of response and recurrence in patients with recurrent highgrade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 2009, 91(3), 329-336.
98. Kang, T. Y.; Jin, T.; Elinzano, H.; Peereboom, D. Irinotecan and bevacizumab in progressiveprimary brain tumors, an evaluation of efficacy and safety. J. Neurooncol. 2008, 89(1), 113-118.
99. Kreisl, T. N.; Kim, L.; Moore, K.; Duic, P.; Royce, C.; Stroud, I.; Garren, N.; Mackey, M.; Butman, J. A.; Camphausen, K.; Park, J.; Albert, P. S.; Fine, H. A. Phase II trial of single-Agent Bevacizumab followed by Bevacizumab plus Irinotecan at tumor progression in recurrent Glioblastoma. J. Clin. Oncol. 2009, 27(5), 740-745.
100. Friedman, H. S.; Prados, M. D.; Wen, P. Y.; Mikkelsen, T.; Schiff, D.; Abrey, L. E.; Yung, W. K.; Paleologos, N.; Nicholas, M. K.; Jensen, R.; Vredenburgh, J.; Huang, J.; Zheng, M.; Cloughesy, T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27(28), 4733-4740.
101. Ali, S. A.; McHayleh, W. M.; Ahmad, A.; Sehgal, R.; Braffet, M.; Rahman, M.; Bejjani, G.; Friedland, D. M. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J. Neurosurg. 2008, 109(2), 268-272.
102. Norden, A. D.; Young, G. S.; Setayesh, K.; Muzikansky, A.; Klufas, R.; Ross, G. L.; Ciampa, A. S.; Ebbeling, L. G.; Levy, B.; Drappatz, J.; Kesari, S.; Wen, P. Y. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70(10), 779-787.
103. Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E.; Dowell, J. M.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D. D.; Friedman, A. H.; Friedman, H. S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13(4), 1253-1259.
104. Desjardins, A.; Reardon, D. A.; Herndon, J. E.; Marcello, J.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Bailey, L.; Bigner, D. D.; Friedman, A. H.; Friedman, H. S.; Vredenburgh, J. J. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin. Cancer Res. 2008, 14(21), 7068-7073.
105. Gutin, P. H.; Iwamoto, F. M.; Beal, K.; Mohile, N. A.; Karimi, S.; Hou, B. L.; Lymberis, S.; Yamada, Y.; Chang, J.; Abrey, L. E. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75(1), 156-163.
106. Cuneo, K. C.; Vredenburgh, J. J.; Sampson, J. H.; Reardon, D. A.; Desjardins, A.; Peters, K. B.; Friedman, H. S.; Willett, C. G.; Kirkpatrick, J. P. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82(5), 2018-2024.
107. Sathornsumetee, S.; Desjardins, A.; Vredenburgh, J. J.; McLendon, R. E.; Marcello, J.; Herndon, J. E.; Mathe, A.; Hamilton, M.; Rich, J. N.; Norfleet, J. A.; Gururangan, S.; Friedman, H. S.; Reardon, D. A. Phase II trial of bevacizumab and erlotinib in patients with recurrentmalignant glioma. Neuro-Oncol. 2010, 12 (12), 1300-1310.
108. Park, K. J.; Kano, H.; Iyer, A.; Liu, X.; Niranjan, A.; Flickinger, J. C.; Lieberman, F.S.; Lunsford, L. D.; Kondziolka, D. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J. Neurooncol. 2012, 107(2), 323-333.
109. Chamberlain, M. C.; Johnston, S. K. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J. Neurooncol. 2010, 96(2), 259-269.
110. Huylebrouck, M.; Lv, S.; Duerinck, J.; Van Binst, A.; Salmon, I.; De Greve, J.; De Witte, O.; Luce, S.; Michotte, A.; D'Haens, J.; Neyns, B. An observational study of the first experience with bevacizumab for the treatment of patients with recurrent high-grade glioma in two belgian university hospitals. J. Oncol. 2012, 2012, 801306.
111. Hofer, S.; Elandt, K.; Greil, R.; Hottinger, A. F.; Huber, U.; Lemke, D.; Marosi, C.; Ochsenbein, A.; Pichler, J.; Roelcke, U.; Weder, P.; Zander, T.; Wick, W.; Weller, M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol. 2011, 50(5), 630-635.
112. Reardon, D. A. M.; Herndon, J. E.; Peters, K.; Desjardins, A.; Coan, A.; Lou, E.; Sumrall, A.; Turner, S.; Sathornsumetee, S.; Rich, J. N.; Boulton, S.; Lipp, E. S.; Friedman, H. S.; Vredenburgh, J. J. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J. Neurooncol. 2012, 107(1), 213-221.
113. Lorgis, V.; Maura, G.; Coppa, G.; Hassani, K.; Taillandier, L.; Chauffert, B.; Apetoh, L.; Ladoire, S.; Ghiringhelli, F. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J. Neurooncol. 2012, 107(2), 351-358.
114. Gil, M. J.; de Las Peñas, R.; Reynés, G.; Balañá, C.; Peréz-Segura, P.; García-Velasco, A.; Mesia, C.; Gallego, O.; Fernández-Chacón, C.; Martínez-García, M.; Herrero, A.; Andrés, R.; Benavides, M.; Quintanar, T.; Pérez-Martin, X. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs 2012, 23(6), 659-665.
115. Reardon, D. A.; Desjardins, A.; Peters, K. B.; Gururangan, S.; Sampson, J. H.; McLendon, R. E.; Herndon, J. E.; Bulusu, A.; Threatt, S.; Friedman, A. H.; Vredenburgh, J. J.; Friedman, H. S. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J. Neurooncol. 2012, 107(1), 155-164.
116. Desjardins, A.; Reardon, D. A.; Coan, A.; Marcello, J.; Herndon, J. E.; Bailey, L.; Peters, K. B.; Friedman, H. S.; Vredenburgh, J. J. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012, 118(5), 1302-1312.
117. Thompson, E. M.; Frenkel, E. P.; Neuwelt, E. A. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011, 78(1), 87-93.
118. Jeyaretna, D. S.; Curry, W. T.; Batchelor, T. T.; Stemmer-Rachamimov, A.; Plotkin, S. R. Exacerbation of Cerebral Radiation Necrosis by Bevacizumab. J. Clin. Oncol. 2011, 29(7), 159-162.
119. Reardon, D. A.; Fink, K. L.; Mikkelsen, T.; Cloughesy, T. F.; O'Neill, A.; Plotkin, S.; Glantz, M.; Ravin, P.; Raizer, J. J.; Rich, K. M.; Schiff, D.; Shapiro, W. R.; Burdette-Radoux, S.; Dropcho, E. J.; Wittemer, S. M.; Nippgen, J.; Picard, M.; Nabors, L. B. Randomized phase II study of cilengitide, an integrin-targeting arginineglycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 2008, 26(34), 5610-5617.
120. Gilbert, M. R.; Kuhn, J.; Lamborn, K. R.; Lieberman, F.; Wen, P. Y.; Mehta, M.; Cloughesy, T.; Lassman, A. B.; Deangelis, L. M.; Chang, S.; Prados, M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J. Neurooncol. 2012, 106(1), 147-153.
121. Stupp, R.; Hegi, M. E.; Neyns, B.; Goldbrunner, R.; Schlegel, U.; Clement, P. M.; Grabenbauer, G. G.; Ochsenbein, A. F.; Simon, M.; Dietrich, P. Y.; Pietsch, T.; Hicking, C.; Tonn, J. C.; Diserens, A. C.; Pica, A.; Hermisson, M.; Krueger, S.; Picard, M.; Weller, M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28(16), 2712-2718.
122. Nabors, L. B.; Mikkelsen, T.; Hegi, M. E.; Ye, X.; Batchelor, T.; Lesser, G.; Peereboom, D.; Rosenfeld, M. R.; Olsen, J.; Brem, S.; Fisher, J. D.; Grossman, S. A. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012 [Epub ahead of print].
123. Wick, W.; Puduvalli, V. K.; Chamberlain, M. C.; van den Bent, M. J.; Carpentier, A. F.; Cher, L. M.; Mason, W.; Weller, M.; Hong, S.; Musib, L.; Liepa, A. M.; Thornton, D. E.; Fine, H. A. Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. J. Clin. Oncol. 2010, 28(7), 1168-1174.
124. Graff, J. R.; McNulty, A. M.; Hanna, K. R.; Konicek, B. W.; Lynch, R. L.; Bailey, S. N.; Banks, C.; Capen, A.; Goode, R.; Lewis, J. E.; Sams, L.; Huss, K. L.; Campbell, R. M.; Iversen, P. W.; Neubauer, B. L.; Brown, T. J.; Musib, L.; Geeganage, S.; Thornton, D. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005, 65(16), 7462-7469.
125. Keyes, K. A.; Mann, L.; Sherman, M.; Galbreath, E.; Schirtzinger, L.; Ballard, D.; Chen, Y. F.; Iversen, P.; Teicher, B. A. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol. 2004, 53(2), 133-140.
126. Teicher, B. A.; Alvarez, E.; Menon, K.; Esterman, M. A.; Considine, E.; Shih, C.; Faul, M. M. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother. Pharmacol. 2002, 49(1), 69-77.
127. Hainsworth, J. D.; Ervin, T.; Friedman, E.; Priego, V.; Murphy, P. B.; Clark, B. L. Lamar, R. E. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the firstline treatment of patients with glioblastoma multiforme. Cancer 2010, 116(15), 3663-3669.
128. Gerstner, E. R.; Eichler, A. F.; Plotkin, S. R.; Drappatz, J.; Doyle, C. L.; Xu, L.; Duda, D. G.; Wen, P. Y.; Jain, R. K.; Batchelor, T. T. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J. Neurooncol. 2010, 103(2), 325-332.
129. Dresemann, G.; Weller, M.; Rosenthal, M. A.; Wedding, U.; Wagner, W.; Engel, E.; Heinrich, B.; Mayer-Steinacker, R.; Karup-Hansen, A.; Fluge, O.; Nowak, A.; Mehdorn, M.; Schleyer, E.; Krex, D.; Olver, I. N.; Steinbach, J. P.; Hosius, C.; Sieder, C.; Sorenson, G.; Parker, R.; Nikolova, Z. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 2010, 96(3), 393-402.
130. Raymond, E.; Brandes, A. A.; Dittrich, C.; Fumoleau, P.; Coudert, B.; Clement, P. M.; Frenay, M.; Rampling, R.; Stupp, R.; Kros, J. M.; Heinrich, M. C.; Gorlia, T.; Lacombe, D.; van den Bent, M. J. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European organisation for research and treatment of cancer brain tumor group study. J. Clin. Oncol. 2008, 26(28), 4659-4665.
131. Neyns, B.; Sadones, J.; Chaskis, C.; Dujardin, M.; Everaert, H.; Lv, S.; Duerinck, J.; Tynninen, O.; Nupponen, N.; Michotte, A.; De Greve, J. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J. Neurooncol. 2011, 103(3), 491-501.
132. Lu-Emerson, C.; Norden, A. D.; Drappatz, J.; Quant, E. C.; Beroukhim, R.; Ciampa, A. S.; Doherty, L. M.; Lafrankie, D. C.; Ruland, S.; Wen, P. Y. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J. Neurooncol. 2011, 104(1), 287-291.
133. Iwamoto, F. M.; Lamborn, K. R.; Robins, H. I.; Mehta, M. P.; Chang, S. M.; Butowski, N. A.; Deangelis, L. M.; Abrey, L. E.; Zhang, W. T.; Prados, M. D.; Fine, H. A. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010, 12(8), 855-861.
134. Batchelor, T. T.; Duda, D. G.; di Tomaso, E.; Ancukiewicw, M.; Plotkin, S. R.; Gerstner, E.; Eichler, A. F.; Drappatz, J.; Hochberg, F. H.; Benner, T.; Louis, D. N.; Cohen, K. S.; Chea, H.; Exarhopoulos, A.; Loeffler, J. S.; Moses, M. A.; Ivy, P.; Sorensen, A. G.; Wen, P. Y.; Jain, R. K. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 2010, 28(17), 2817-2823.
135. Ahluwalia, M. S. 2010 Society for neuro-oncology annual meeting: a report of selected studies. Expert Rev. Anticancer Ther. 2011, 11(2), 161-163.
136. Fine, H. A.; Kim, L.; Albert, P. S.; Duic, J. P.; Ma, H.; Zhang, W.; Tohnya, T.; Figg, W. D.; Royce, C. A phase I trial of lenalidomide in patients with recurrent primary central nervous systemtumors. Clin. Cancer Res. 2007, 13(23), 7101-7106.
137. Puduvalli, V. K.; Giglio, P.; Groves, M. D.; Hess, K. R.; Gilbert, M. R.; Mahankali, S.; Jackson, E. F.; Levin, V. A.; Conrad, C. A.; Hsu, S. H.; Colman, H.; de Groot, J. F.; Ritterhouse, M. G.; Ictech, S. E.; Yung, W. K. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008, 10(2), 216-222.
138. Fine, H. A.; Wen, P. Y.; Maher, E. A.; Viscosi, E.; Batchelor, T.; Lakhani, N.; Figg, W. D.; Purow, B. W.; Borkowf, C. B. Phase II trial of thalidomide and carmustine for patients with recurrent high grade gliomas. J. Clin. Oncol. 2003, 21(12), 2299-2304.
139. Fine, H. A.; Figg, W. D.; Jaeckle, K.; Wen, P. Y.; Kyritsis, A. P.; Loeffler, J. S.; Levin, V. A.; Black, P. M.; Kaplan, R.; Pluda, J. M.; Yung, W. K. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 2000, 18(4), 708-715.
140. Lorimer, I. A.; Wikstrand, C. J.; Batra, S. K.; Bigner, D. D.; Pastan, I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin. Cancer Res. 1995, 1(8), 859-864.
141. Mishima, K.; Johns, T. G.; Luwor, R. B.; Scott, A. M.; Stockert, E.; Jungbluth, A. A.; Ji, X. D.; Suvarna, P.; Voland, J. R.; Old, L. J.; Huang, H. J.; Cavenee, W. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001, 61(14), 5349-5354.
142. Nagane, M.; Narita, Y.; Mishima, K.; Levitzki, A.; Burgess, A. W.; Cavenee, W. K.; Huang, H. J. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J. Neurosurg. 2001, 95(3), 472-479.
143. Jungbluth, A. A.; Stockert, E.; Huang, H. J.; Collins, V. P.; Coplan, K.; Iversen, K.; Kolb, D.; Johns, T. J.; Scott, A. M.; Gullick, W. J.; Ritter, G.; Cohen, L.; Scanlan, M. J.; Cavenee, W. K.; Old, L. J. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 2003, 100(2), 639-644.
144. Li, S.; Schmitz, K. R.; Jeffrey, P. D.; Wiltzius, J. J.; Kussie, P.; Ferguson, K. M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7(4), 301-311.
145. Combs, S. E.; Schulz-Ertner, D.; Roth, W.; Herold-Mende, C.; Debus, J.; Weber, K. J. In vitro responsiveness of glioma cell lines multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68(3), 873-882.
146. Eller, J. L.; Longo, S. L.; Kyle, M. M.; Bassano, D.; Hicklin, D. J.; Canute, G. W. Anti-Epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 2005, 56(1), 155-162.
147. Belda-Iniesta, C.; Carpeno, J. C.; Saenz, E. C.; Gutiérrez, M.; Perona, R.; Barón, M. G. Long therm responses with cetuximab therapy in glioblastoma multiforme. Cancer. Biol. Ther. 2006, 5(8), 912-914.
148. Hasselbalch, B.; Lassen, U.; Hansen, S.; Holmberg, M.; Sørensen, M.; Kosteljanetz, M.; Broholm, H.; Stockhausen, M. T.; Poulsen, H. S. Cetuximab, bevacizumab, and iriniotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trials. Neuro Oncol. 2010, 12(5), 508-516.
149. Brown, P. D.; Krishnan, S.; Sarkaria, J. N.; Wu, W.; Jaeckle, K. A.; Uhm, J. H.; Geoffroy, F. J.; Arusell, R.; Kitange, G.; Jenkins, R. B.; Kugler, J. W.; Morton, R. F.; Rowland, K. M.; Mischel, P.; Yong, W. H.; Scheithauer, B. W.; Schiff, D.; Giannini, C.; Buckner, J. C. Phase I/II trial of Erlotinib and Temozolomide with radiation therapy in the treatment of newly diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 2008, 26(34), 5603-5609.
150. Peereboom, D. M.; Shepard, D. R.; Ahluwalia, M. S.; Brewer, C. J.; Agarwal, N.; Stevens, G. H.; Suh, J. H.; Toms, S. A.; Vogelbaum, M. A.; Weil, R. J.; Elson, P.; Barnett, G. H. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol. 2010, 98(1), 93-99.
151. Prados, M. D.; Chang, S. M.; Butowski, N.; DeBoer, R.; Parvataneni, R.; Carliner, H.; Kabuubi, P.; Ayers-Ringler, J.; Rabbitt, J.; Page, M.; Fedoroff, A.; Sneed, P. K.; Berger, M. S.; McDermott, M. W.; Parsa, A. T.; Vandenberg, S.; James, C. D.; Lamborn, K. R.; Stokoe, D.; Haas-Kogan, D. A. Phase II Study of Erlotinib plus Temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 2009, 27(4), 579-584.
152. Prados, M. D.; Yung, W. K.; Wen, P. Y.; Junck, L.; Cloughesy, T.; Fink, K.; Chang, S.; Robins, H. I.; Dancey, J.; Kuhn, J. Phase-I trial of gefitinib and temozolomide in patients with malignant glioma: a North american brain tumor consortium study. Cancer Chemother. Pharmacol. 2008, 61(6), 1059-1067.
153. Uhm, J. H.; Ballman, K. V.; Wu, W.; Giannini, C.; Krauss, J. C.; Buckner, J. C.; James, C. D.; Scheithauer, B. W.; Behrens, R. J.; Flynn, P. J.; Schaefer, P. L.; Dakhill, S. R.; Jaeckle, K. A. Phase II Evaluation of Gefitinib in Patients with Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int. J. Radiat. Oncol. Biol. Phys. 2010, 80(2), 347-353.
154. Haas-Kogan, D. A.; Prados, M. D.; Tihan, T.; Eberhard, D. A.; Jelluma, N.; Arvold, N. D.; Baumber, R.; Lamborn, K. R.; Kapadia, A.; Malec, M.; Berger, M. S.; Stokoe, D. Epidermal growth factor receptor, protein Kinase B/Akt, and Glioma response to Erlotinib. J. Natl. Cancer Inst. 2005, 97(12), 880-887.
155. van den Bent, M. J.; Brandes, A. A.; Rampling, R.; Kouwenhoven, M. C.; Kros, J. M.; Carpentier, A. F.; Clement, P. M.; Frenay, M.; Campone, M.; Baurain, J. F.; Armand, J. P.; Taphoorn, M. J.; Tosoni, A.; Kletzl, H.; Klughammer, B.; Lacombe, D.; Gorlia, T. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J. Clin. Oncol. 2009, 27(8), 1268-1274.
156. Rich, J. N.; Reardon, D. A.; Peery, T.; Dowell, J. M.; Quinn, J. A.; Penne, K. L.; Wikstrand, C. J.; Van Duyn, L. B.; Dancey, J. E.; McLendon, R. E.; Kao, J. C.; Stenzel, T. T.; Ahmed Rasheed, B. K.; Tourt-Uhlig, S. E.; Herndon, J. E.; Vredenburgh, J. J.; Sampson, J. H.; Friedman, A. H.; Bigner, D. D.; Friedman, H. S. Phase II trial of Gefitinib in recurrent Glioblastoma. J. Clin. Oncol. 2004, 22(1), 133-142.
157. Mellinghoff, I. K.; Wang, M. Y.; Vivanco, I.; Haas-Kogan, D. A.; Zhu, S.; Dia, E. Q.; Lu, K. V.; Yoshimoto, K.; Huang, J. H.; Chute, D. J.; Riggs, B. L.; Horvath, S.; Liau, L. M.; Cavenee, W. K.; Rao, P. N.; Beroukhim, R.; Peck, T. C.; Lee, J. C.; Sellers, W. R.; Stokoe, D.; Prados, M.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S. Molecular determinants of the response of Glioblastomas to EGFR Kinase inhibitors. N. Engl. J. Med. 2005, 353(19), 2012-2024.
158. Taylor, T. E.; Furnari, F. B.; Cavenee, W. K. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr. Cancer Drug Targets 2012, 12(3), 197-209.
159. Krakstad, C.; Chekenya, M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol. Cancer 2010, 9(135), 1-14.
160. Stommel, J. M.; Kimmelman, A. C.; Ying, H.; Nabioullin, R.; Ponugoti, A. H.; Wiedemeyer, R.; Stegh, A. H.; Bradner, J. E.; Ligon, K. L.; Brennan, C.; Chin, L.; DePinho, R. A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318(5848), 287-290.
161. Lo, H. W.; Cao, X.; Zhu, H.; Ali-Osman, F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin. Cancer Res. 2008, 14(19), 6042-6054.
162. Lo, H. W. EGFR-Targeted Therapy in Malignant Glioma Current Molecular Pharmacology. Curr. Mol. Pharmacol. 2010, 3(1) 37-52.
163. Dimitroulakos, J.; Lorimer, I. A.; Goss, G. Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin. Cancer Res. 2006, 12(14), 4426-4431.
164. Hopper-Borge, E. A.; Nasto, R. E.; Ratushny, V.; Weiner, L. M. Golemis, E. A. Astsaturov, I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin. Ther. Targets 2009, 13(3), 339-362.
165. Cao, X.; Zhu, H.; Ali-Osman, F.; Lo, H. W. EGFR and EGFRvIII undergo stress-and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. Mol. Cancer 2011, 10(26), 1-13.
166. Galanis, E.; Buckner, J. C.; Maurer, M. J.; Kreisberg, J. I.; Ballman, K.; Boni, J.; Peralba, J. M.; Jenkins, R. B.; Dakhil, S. R.; Morton, R. F.; Jaeckle, K. A.; Scheithauer, B. W.; Dancey, J.; Hidalgo, M.; Walsh, D. J. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2005, 23(23), 5294-5304.
167. Chang, S. M.; Wen, P.; Cloughesy, T.; Greenberg, H.; Schiff, D.; Conrad, C.; Fink, K.; Robins, H. I.; De Angelis, L.; Raizer, J.; Hess, K.; Aldape, K.; Lamborn, K. R.; Kuhn, J.; Dancey, J.; Prados, M. D. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 2005, 23(4), 357-361.
168. Sarkaria, J. N.; Galanis, E.; Wu, W.; Dietz, A. B.; Kaufmann, T. J.; Gustafson, M. P.; Brown, P. D.; Uhm, J. H.; Rao, R. D.; Doyle, L.; Giannini, C.; Jaeckle, K. A.; Buckner, J. C. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin. Cancer Res. 2010, 16(22), 5573-5580.
169. Rao, R.; Mladek, A.; Lamont, J.; Goble, J. M.; Erlichman, C.; James, C. D.; Sarkaria, J. N. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005, 7(10), 921-929.
170. Reardon, D. A.; Quinn, J. A.; Vredenburgh, J. J.; Gururangan, S.; Friedman, A. H.; Desjardins, A.; Sathornsumetee, S.; Herndon, J. E.; Dowell, J. M.; McLendon, R. E.; Provenzale, J. M.; Sampson, J. H.; Smith, R. P.; Swaisland, A. J.; Ochs, J. S.; Lyons, P.; Tourt-Uhlig, S.; Bigner, D. D.; Friedman, H. S.; Rich, J. N. Phase I Trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. 2006, 12(3), 860-868.
171. Doherty, L.; Gigas, D. C.; Kesari, S.; Drappatz, J.; Kim, R.; Zimmerman, J.; Ostrowsky, L.; Wen, P. Y. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006, 67(1), 156-158.
172. Wang, M. Y.; Lu, K. V.; Zhu, S.; Dia, E. Q.; Vivanco, I.; Shackleford, G. M.; Cavenee, W. K.; Mellinghoff, I. K.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S. Mammalian target of Rapamycin inhibition promotes response to epidermal growth factor receptor Kinase inhibitors in PTEN-Deficient and PTENIntact Glioblastoma cells. Cancer Res. 2006, 66(16), 7864-7869.
173. Kreisl, T. N.; Lassman, A. B.; Mischel, P. S.; Rosen, N.; Scher, H. I.; Teruya-Feldstein, J.; Shaffer, D.; Lis, E.; Abrey, L. E. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 2009, 92(1), 99-105.